October 1, 2014 — Heart Hospital of Austin is the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA) -approved HF monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage HF.

October 1, 2014 — St. Johns Hospital and Medical Center in Detroit recently became the first U.S. healthcare facility to install the Artis one angiography system from Siemens Healthcare. The Artis one is designed to address a broad range of angiographic procedures, from diagnosing and treating coronary artery disease and peripheral vessel occlusions to performing electrophysiology procedures.

Backus Hospital, Hartford Hospital, The Hospital of Central Connecticut, MidState Medical Center, and Windham Hospital now gather and analyze dose data from all necessary modalities within their imaging departments to ensure an effective dose management program for their patients through the use of Sectra DoseTrack.

Although most accountable care organizations have the health information technology to improve clinical quality, poor interoperability across systems and providers remains a barrier, according to an ACO survey conducted by Premier Inc. and the eHealth Initiative. 

September 30, 2014 — The American College of Cardiology (ACC), along with eight partnering societies, released the first appropriate use criteria (AUC) for suspected heart disease in pediatric patients.

September 30, 2014 — Acist Medical Systems Inc. showcased the HDi high-definition intravascular ultrasound system (HD-IVUS) in two live cases at the recent 2014 Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

iFR
iFR
iFR

Earlier this year, the Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis adopted the instant wave-Free Ratio (iFR) technology. The iFR modality is a pressure-derived hyperemia-free index for assessment of coronary stenosis relevance. 

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now